Congress Materials – AM (AM-2024)
2024 AM | May 31-Jun 4 | Chicago, IL
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Amivantamab Plus Capmatinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring MET Alterations: Recommended Phase 2 Combination Dose and Preliminary Dose-Escalation Results From the Phase 1/2 METalmark Study
Alexander I. Spira, Byoung Chul Cho, Tae Min Kim, Sang-We Kim, Bing Xia, Eunice Artis, Jessica Dobbs, Christine Baudelet, Mahadi Baig, Joshua M. Bauml, Mehmet Ali Sendur
Amivantamab Plus Chemotherapy vs Chemotherapy as First-Line Treatment Among Patients With EGFR Exon 20 Insertion-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC): PAPILLON Chinese Subgroup Analysis
Ke-Jing Tang, Baogang Liu, Yu Yao, Yanqiu Zhao, Jianying Zhou, Ping Sun, Donglin Wang, Dongqing Lv, Huijie Wang, Yi Hu, Qiang Li, Yujiao Song, Grace Gao, Liyun Wang, Trishala Agrawal, Archan Bhattacharya, Mahadi Baig, Patricia Lorenzini, Honeylet Wortman-Vayn, Caicun Zhou
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC): Results From CHRYSALIS-2
Byoung Chul Cho, Yongsheng Wang, Enriqueta Felip, Jiuwei Cui, Alexander I. Spira, Joel W Neal, Christina Baik, Melina E. Marmarelis, Eiki Ichihara, Jong-Seok Lee, Se-Hoon Lee, James Chih-Hsin Yang, Sebastian Michels, Zacharias Anastasiou, Joshua C. Curtin, Xuesong Lyu, Levon Demirdjian, Isabelle Leconte, Leonardo Trani, Mahadi Baig, Joshua M. Bauml, Pascale Tomasini
Amivantamab Plus Lazertinib vs Osimertinib in First-Line EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) With Biomarkers of High-Risk Disease: A Secondary Analysis From the Phase 3 MARIPOSA Study
Enriqueta Felip, Byoung Chul Cho, Vanesa Gutiérrez, Adlinda Alip, Benjamin Besse, Shun Lu, Alexander I. Spira, Nicolas Girard, Raffaele Califano, Shirish M. Gadgeel, James Chih-Hsin Yang, Naoyuki Nogami, Koichi Azuma, Joshua C. Curtin, Jiarui Zhang, Anesh Panchal, Mariah Ennis, Seema Sethi, Joshua M. Bauml, Se-Hoon Lee
A Phase 1 Study of JNJ-69086420, an 225Ac-Labeled Antibody Targeting Human Kallikrein 2 to Treat Metastatic Castration-Resistant Prostate Cancer
Michael J. Morris, Jeffrey Y.C. Wong, Luke T. Nordquist, Russell Z. Szmulewitz, Neeraj Agarwal, Edward F. Attiyeh, Steven Max, Chaitanya R. Divgi, Daniel Patricia, Yu Cao, Xiang Li, Alex Yu, Karen Urtishak, Josh D. Lauring, A. Oliver Sartor
Ciltacabtagene Autoleucel in Patients With Lenalidomide-Refractory Multiple Myeloma: CARTITUDE-2 Cohort A Expansion Subgroup
Adam D. Cohen, Peter M. Voorhees, Thomas G. Martin, Alexander M. Lesokhin, Jens Hillengass, Jonathan L. Kaufman, Jordan M. Schecter, Kevin C. De Braganca, Helen Varsos, Christina Corsale, Pankaj Mistry, Qingxuan Song, Mythili Koneru, Muhammad Akram, Octavio Costa Filho, Hermann Einsele
Ciltacabtagene Autoleucel vs Standard of Care in Patients With Functional High-Risk Multiple Myeloma: CARTITUDE-4 Subgroup Analysis
Luciano J. Costa, Katja Weisel, Niels W.C.J. van de Donk, Surbhi Sidana, Yaël C. Cohen, Duncan Purtill, Cyrille Touzeau, Carlos Fernández de Larrea, Joaquin Martinez-Lopez, Nikoletta Lendvai, Ana Slaughter, Carolina Lonardi, Man Zhao, Katherine Li, Martin Vogel, Mythili Koneru, Nitin Patel, Erika Florendo, Octavio Costa Filho, María-Victoria Mateos
Clinical Characteristics and Treatment Patterns of High-Risk Prostate Cancer (HR LPC) Patients Treated With Radical Prostatectomy (RP) and Perioperative Hormonal Therapy (HT) in Japan, South Korea, and Taiwan
Shingo Hatakeyama, Seung Hwan Lee, Chun-Te Wu, Wen-Cheng Chen, Jae Hoon Chung, Seong Soo Jeon, Minji Lee, Ji Youl Lee, Hyong Woo Moon, Shintaro Narita, Hayato Yamamoto, Carine Saadoun, Anildeep Singh, Jianmin Zhuo, Cindy Thiow Koon Lim, Tomonori Habuchi
Daratumumab (DARA) + Bortezomib/Lenalidomide/Dexamethasone (VRd) With DARA-R (D-R) Maintenance in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma (NDMM): Minimal Residual Disease (MRD) Analysis in the PERSEUS Trial
Paula Rodriguez-Otero, Philippe Moreau, Meletios A Dimopoulos, Meral Beksac, Aurore Perrot, Annemiek Broijl, Francesca Gay, Roberto Mina, Niels WCJ van de Donk, Fredrik Schjesvold, Michel Delforge, Hermann Einsele, Andrew Spencer, Sarah Lonergan, Diego Vieyra, Anna Sitthi-Amorn, Robin Carson, Joan Bladé, Mario Boccadoro, Pieter Sonneveld
Efficacy and Safety of Ciltacabtagene Autoleucel ± Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma With Suboptimal Response to Frontline Autologous Stem Cell Transplant: CARTITUDE-2 Cohort D
Bertrand Arnulf, Tessa Kerre, Mounzer Agha, Michel Delforge, Ira Braunschweig, Nishi Shah, Shambavi Richard, Melissa Alsina, Hermann Einsele, Pankaj Mistry, Helen Varsos, Christina Corsale, Jordan M. Schecter, Kevin C De Braganca, Yogesh Jethava, Qingxuan Song, Mythili Koneru, Muhammad Akram, Yaël C. Cohen, Wilfried Roeloffzen
Efficacy and Safety of Erdafitinib in Adults With Breast Cancer and Prespecified Fibroblast Growth Factor Receptor Alterations in the Phase 2 Open-Label, Single-Arm RAGNAR Trial
Omar Carranza, Martin Schuler, Josep Tabernero, Yohann Loriot, Dirk Arnold, Gunnar Folprecht, Daniel Palmer, Graziela Z. Dal Molin, Martin Gutierrez, Hans Prenen, Iwona Lugowska, Andres Cervantes, Hussein Sweiti, Constance Hammond, Saltanat Najmi, Shibu Thomas, Spyros Triantos, Lauren Crow, Shubham Pant
Efficacy and Safety of Erdafitinib in Adults With NSCLC and Prespecified Fibroblast Growth Factor Receptor Alterations in the Phase 2 Open-Label, Single-Arm RAGNAR Trial
Martin Schuler, Josep Tabernero, Omar Carranza, Yohann Loriot, Shubham Pant, Dirk Arnold, Gunnar Folprecht, Daniel Palmer, Hans Prenen, Graziela Z. Dal Molin, Iwona Ługowska, Andrés Cervantes, Hussein Sweiti, Constance Hammond, Saltanat Najmi, Shibu Thomas, Spyros Triantos, Karen Xia, Martin Gutierrez
Efficacy and Safety of Erdafitinib in Patients With Advanced or Metastatic Cholangiocarcinoma and FGFR Alterations: Pooled Analysis of RAGNAR and LUC2001 Studies
Shubham Pant, Joon Oh Park, Wu-Chou Su, Martin Schuler, Yohann Loriot, Gopa Iyer, Toshihiko Doi, Shukui Qin, Josep Tabernero, Hans Prenen, Gunnar Folprecht, Helen Winter, Graziela Z. Dal Molin, Hussein Sweiti, Saltanat Najmi, Constance Hammond, Huimin Liao, Shibu Thomas, Spyros Triantos, Yin-Hsun Feng
Efficacy and Safety of Erdafitinib in Pediatric Patients With Advanced Solid Tumors and FGFR Alterations in the Phase 2 RAGNAR Trial
Olaf Witt, Sameer Farouk Sait, Blanca Diez, Agustin Cardoso, David A. Reardon, Liam Welsh, Kent Shih, Capucine Baldini, Christophe Massard, Yohann Loriot, Shubham Pant, Hussein Sweiti, Shibu Thomas, Constance Hammond, Saltanat Najmi, Spyros Triantos, Lauren Crow, Birgit Geoerger
Efficacy and Safety of Ibrutinib Plus Venetoclax in Patients With Mantle Cell Lymphoma and TP53 Mutations in the SYMPATICO Study
Michael Wang, Wojciech Jurczak, Marek Trneny, David Belada, Tomasz Wrobel, Nilanjan Ghosh, Mary-Margaret Keating, Tom van Meerten, Ruben Fernandez Alvarez, Gottfried von Keudell, Catherine Thieblemont, Frederic Peyrade, Marc Andre, Marc Hoffmann, Maoko Naganuma, Edith Szafer-Glusman, Jennifer Lin, James P. Dean, Jutta K. Neuenburg, Constantine S. Tam
Efficacy of Erdafitinib in Adults with Advanced Solid Tumors and Non-Prespecified Fibroblast Growth Factor Receptor Mutations in the Phase 2 RAGNAR Trial: Exploratory Cohort
Iwona Lugowska, Martin Schuler, Yohann Loriot, Omar Carranza, Gopa Iyer, Toshihiko Doi, Shukui Qin, Josep Tabernero, David A. Reardon, Christophe Massard, Dirk Arnold, Martin Gutierrez, Helen Winter, Hussein Sweiti, Karen Xia, Saltanat Najmi, Constance Hammond, Shibu Thomas, Spyros Triantos, Shubham Pant
FGFR3 Alterations (FGFRalt) in Patients (Pts) Who Develop Locally Advanced or Metastatic Urothelial Cancer (mUC), and Their Association With Tumor Subtype and Clinical Outcomes in Patients Treated With Erdafitinib (Erda) vs. Pembrolizumab (Pembro)
Arlene Siefker-Radtke, Yohann Loriot, Nobuaki Matsubara, Se Hoon Park, Robert A. Huddart,Earle F. Burgess, Jiarui Zhang, Neil Beeharry, Shibu Thomas, Nicole Stone, Kris Deprince, Spyros Triantos, Woonyoung Choi
Inferring PDL-1 Status from H&E Images Using Digital Pathology to Identify Patients Responsive to Anti-PD(L)-1 Immuno-oncology Therapy for Bladder Cancer Trials
Albert Juan Ramon, Brandon Ginley, Madhawa Saranadasa, Chaitanya Parmar, Neil Beeharry, Shibu Thomas, Bolan Linghu, Joel Greshock, Kristopher Standish
LIBERTAS, a Degendered and Transgender-Inclusive Phase 3 Study of Apalutamide Plus Intermittent Versus Continuous Androgen Deprivation Therapy in Participants With Metastatic Hormone-Sensitive Prostate Cancer
Arun Azad, Clark Musto, Shir Netanel, Tian Zhang, Dana E. Rathkopf, Marco Antonio Badillo, Qiang Dong, Alicia K. Morgans, Karie Runcie, Alex Dos Santos, Amitabha Bhaumik, Suneel D. Mundle, Sharon A. McCarthy, Angela Lopez-Gitlitz, Ashita S. Batavia, Daniel P. Sanchez, Mark Wildgust, Neeraj Agarwal
Longer-Term Follow-Up of Patients Receiving Prophylactic Tocilizumab for the Reduction of Cytokine Release Syndrome in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma
Niels W.C.J. van de Donk, Alfred L. Garfall, Lotfi Benboubker, Katarina Uttervall, Kaz Groen, Laura Rosiñol, Jeffrey Matous, Deeksha Vishwamitra, Caroline Hodin, Tara Stephenson, Keqin Qi, Athena Zuppa, Katherine Chastain, María-Victoria Mateos
Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma
Alfred L. Garfall, Ajay K. Nooka, Niels WCJ van de Donk, Philippe Moreau, Manisha Bhutani, Albert Oriol, Thomas G. Martin, Laura Rosiñol, María-Victoria Mateos, Nizar J. Bahlis, Rakesh Popat, Britta Besemer, Joaquin Martinez-Lopez, Amrita Y. Krishnan, Michel Delforge, Lin Huang, Deeksha Vishwamitra, Tara Stephenson, Katherine Chastain, Surbhi Sidana
Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma: Up to 5.5 Years of Follow-up in the Phase 2 CAPTIVATE Study
William G. Wierda, Ryan Jacobs, Paul M. Barr, John N. Allan, Tanya Siddiqi, Alessandra Tedeschi, Thomas J. Kipps, Susan M. O'Brien, Xavier C. Badoux, Andrea Visentin, Masa Lasica, Dennis Carney, Anna Elinder Camburn, Javier De la Serna, Edith Szafer-Glusman, Cathy Zhou, Anita Szoke, James P. Dean, Paolo Ghia, Constantine S. Tam
PHAROS, A Real-World Multi-Country European Study on Patients With High-Risk Localised and Locally Advanced Prostate Cancer Receiving Radical Treatment
Matthias Eiber, Daniel M. Aebersold, Alfonso Valcarcel Diaz, Christian Wetterauer, Michael Bach, Flavio Camarrone, Kathleen Herkommer, Honghao Li, Fernando Lopez Campos, Thomas Mathieu, Jonathan Olivier, Geneviève Pissart, Paul Robinson, Mohamed Shelan, Hind Stitou, Céline Thiriez, Maxime Touzot, Arnauld Villers
Prospective Iterative Data Visualization Study to Enhance Health Literacy in Prostate Cancer
Daniel E. Spratt, Patrick J. Bingham, John Eckardt, Shelby Moneer, Matthew J. Pagano, Kirsten York
Rapid and Deep Prostate-Specific Antigen (PSA) Response to Apalutamide Plus ADT Correlates With Improved Survival in Metastatic Castration-Sensitive Prostate Cancer (mCSPC) in Real World Practice in the US (OASIS Project)
Benjamin L. Maughan, Yanfang Liu, Suneel Mundle, Xiayi Wang, Lawrence Karsh
Real-World Less Frequent Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma
Carlyn Rose Tan, Andriy Derkach, Kylee Maclachlan, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi Shah, Sridevi Rajeeve, Gunjan L. Shah, Michael Scordo, David J. Chung, Heather J. Landau, Sergio A. Giralt, Alexander Lesokhin, Neha Korde, Dee Lin, Bingcao Wu, Jessica Fowler, Mariana Fernandez, Saad Z. Usmani
Results From Safety Run-In Cohort 1 of the Phase 3 MajesTEC-7 Study in Patients With Transplant Ineligible/Not Intended Newly Diagnosed Multiple Myeloma
Cyrille Touzeau, Meral Beksac, Evangelos Terpos, Saad Z. Usmani, Amrita Y. Krishnan, Inger S. Nijhof, Wojciech Janowski, Cyrille Hulin, Sebastian Grosicki, Michel Delforge, Dana McAleer, Sarah Nagle, Sarah Broskin, Yunsi Olyslager, Jonathan Miller, Zoe Craig, Josephine Khan, Tobias Kampfenkel, Salomon Manier, Niels WCJ van de Donk
Subcutaneous Amivantamab and Lazertinib as First-Line Treatment in Patients With EGFR-Mutated, Advanced Non-Small Cell Lung Cancer (NSCLC): Interim Results From the Phase 2 PALOMA-2 Study
Sun Min Lim, Jiunn Liang Tan, Josiane Mourão Dias, Pei Jye Voon, Soon Hin How, Xiangdong Zhou, Hailin Xiong, Bartomeu Massutí, Louise Medley, Misako Nagasaka, David Vicente, Nicolas Girard, Achim Rittmeyer, Dana-Adriana Botesteanu, Ali Alhadab, Janine Mahoney, Jie Zhang, Joshua M. Bauml, Mahadi Baig, Susan C. Scott
Subcutaneous Amivantamab vs Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory EGFR-Mutated, Advanced Non-Small Cell Lung Cancer (NSCLC): Primary Results, Including Overall Survival (OS), From the Global, Phase 3, Randomized Controlled PALOMA-3 Trial
Natasha B. Leighl, Hiroaki Akamatsu, Sun Min Lim, Ying Cheng, Anna R. Minchom, Melina E. Marmarelis, Rachel E. Sanborn, James Chih-Hsin Yang, Baogang Liu, Thomas John, Bartomeu Massutí, Alexander I. Spira, John Xie, Debopriya Ghosh, Ali Alhadab, Remy B. Verheijen, Mohamed Gamil, Joshua M. Bauml, Mahadi Baig, Antonio Passaro
Copies of these presentation are for personal use only and may not be reproduced without permission from ASCO® or the author of this presentation.